Publications by authors named "Vincent Olaf Dezentje"
Article Synopsis
- - Tamoxifen is commonly used in breast cancer treatment, but how effective it is can vary significantly among patients, primarily due to differing levels of its active metabolite, endoxifen.
- - A genome-wide association study (GWAS) involving 608 women aimed to find genetic factors that influence endoxifen levels and patient survival outcomes, revealing multiple significant genetic variants.
- - The study found that certain genetic variants on chromosome 22, including those linked to the CYP2D6 gene, are strongly associated with both endoxifen concentration and relapse-free survival in breast cancer patients on tamoxifen.
Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochrome P450 (CYP) 2D6 enzyme. We prospectively investigated tamoxifen efficacy by serum endoxifen levels and the tamoxifen activity score (TAS). A prospective observational multicenter study included postmenopausal women with an estrogen receptor-positive breast cancer receiving first-line tamoxifen, 20 mg daily in the neoadjuvant or metastatic setting, recruited between February 2009 and May 2014.
View Article and Find Full Text PDF